684 related articles for article (PubMed ID: 27672289)
1. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
2. Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression.
Greco C; Alvino S; Buglioni S; Assisi D; Lapenta R; Grassi A; Stigliano V; Mottolese M; Casale V
Anticancer Res; 2001; 21(5):3185-92. PubMed ID: 11848471
[TBL] [Abstract][Full Text] [Related]
3. Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease.
Sipos F; Fűri I; Constantinovits M; Tulassay Z; Műzes G
World J Gastroenterol; 2014 Sep; 20(36):12713-21. PubMed ID: 25278673
[TBL] [Abstract][Full Text] [Related]
4. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
5. The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.
Kugimiya N; Nishimoto A; Hosoyama T; Ueno K; Enoki T; Li TS; Hamano K
J Cell Mol Med; 2015 Jul; 19(7):1569-81. PubMed ID: 25689483
[TBL] [Abstract][Full Text] [Related]
6. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
[TBL] [Abstract][Full Text] [Related]
7. Depletion of c-Myc inhibits human colon cancer colo 320 cells' growth.
Hongxing Z; Nancai Y; Wen S; Guofu H; Yanxia W; Hanju H; Qian L; Wei M; Yandong Y; Hao H
Cancer Biother Radiopharm; 2008 Apr; 23(2):229-37. PubMed ID: 18454692
[TBL] [Abstract][Full Text] [Related]
8. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
[TBL] [Abstract][Full Text] [Related]
9. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
11. circCTIC1 promotes the self-renewal of colon TICs through BPTF-dependent c-Myc expression.
Zhan W; Liao X; Wang Y; Li L; Li J; Chen Z; Tian T; He J
Carcinogenesis; 2019 Jun; 40(4):560-568. PubMed ID: 30403769
[TBL] [Abstract][Full Text] [Related]
12. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program.
Elliott K; Ge K; Du W; Prendergast GC
Oncogene; 2000 Sep; 19(41):4669-84. PubMed ID: 11032017
[TBL] [Abstract][Full Text] [Related]
13. Oncogene-mediated transformation of fetal rat colon in vitro.
Pories S; Jaros K; Steele G; Pauley A; Summerhayes IC
Oncogene; 1992 May; 7(5):885-93. PubMed ID: 1373876
[TBL] [Abstract][Full Text] [Related]
14. WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability.
Yokota K; Tanaka Y; Harada H; Kaida T; Nakamoto S; Soeno T; Fujiyama Y; Yokota M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Dec; 26(13):4826-4834. PubMed ID: 31549316
[TBL] [Abstract][Full Text] [Related]
15. The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability.
Lee YJ; Lee EY; Choi BH; Jang H; Myung JK; You HJ
Mol Cells; 2020 May; 43(5):459-468. PubMed ID: 32299194
[TBL] [Abstract][Full Text] [Related]
16. The myc 3' wnt-responsive element suppresses colonic tumorigenesis.
Konsavage WM; Yochum GS
Mol Cell Biol; 2014 May; 34(9):1659-69. PubMed ID: 24567369
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.
Gerner EW; Ignatenko NA; Lance P; Hurley LH
Ann N Y Acad Sci; 2005 Nov; 1059():97-105. PubMed ID: 16382048
[TBL] [Abstract][Full Text] [Related]
19. The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
Hoffman B; Amanullah A; Shafarenko M; Liebermann DA
Oncogene; 2002 May; 21(21):3414-21. PubMed ID: 12032779
[TBL] [Abstract][Full Text] [Related]
20. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
